Last updated on July 2019

Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy


Brief description of study

This is a randomized-controlled open-label trial comparing two different doses of low-molecular-weight heparin (LMWH) in pregnant patients with a history of previous venous thromboembolism (VTE). Both doses are recommended doses in the 2012 guidelines of the American College of Chest Physicians (ACCP), but it is not known which dose is more efficacious in preventing recurrent venous thromboembolism in pregnancy.

Patients enter the study and will be randomized as soon as a home test confirms pregnancy. LMWH will be administered until 6 weeks postpartum. Follow-up will continue until 3 months postpartum. Patients will be recruited by their treating physician, either an obstetrician or internist.

Clinical Study Identifier: NCT01828697

Find a site near you

Start Over

La R union - Saint-Denis

Saint-Denis, France
4.83miles
  Connect »

APHP Antoine B cl re

Paris, France
6.37miles
  Connect »

APHP Port Royal

Paris, France
6.37miles
  Connect »

CHU de Poitiers

Paris, France
6.37miles
  Connect »